Evidence map›Paper›PMID 25138064›Full record

Trial reportThe British journal of nutrition2014

Effect of almond consumption on the serum fatty acid profile: a dose-response study.

Stephanie Nishi, Cyril W C Kendall, Ana-Maria Gascoyne, Richard P Bazinet, Balachandran Bashyam, Karen G Lapsley, Livia S A Augustin, John L Sievenpiper, David J A Jenkins

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Almonds (Nutrients · 2020
    Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Stephanie NishiDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
Cyril W C KendallDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
Ana-Maria GascoyneDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
Richard P BazinetDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
Balachandran BashyamDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
Karen G LapsleyThe Almond Board of California,Modesto,CA,USA.
Livia S A AugustinClinical Nutrition and Risk Factor Modification Center, St Michael's Hospital,Toronto,ON,Canada.
John L SievenpiperDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
David J A JenkinsDepartment of Nutritional Sciences,Faculty of Medicine, University of Toronto,Toronto,ON,CanadaM5S 3E2.
University of Toronto · CASt. Michael's Hospital · CAAlmond Board of California · USMcMaster University · CAUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Consumption of almonds has been shown to be associated with a decreased risk of CHD, which may be related to their fatty acid (FA) composition. However, the effect of almond consumption on the serum FA composition is not known. Therefore, in the present study, we investigated whether almond consumption would alter the serum FA profile and risk of CHD, as calculated using Framingham's 10-year risk score, in a dose-dependent manner in hyperlipidaemic individuals when compared with a higher-carbohydrate control group using dietary interventions incorporating almonds. A total of twenty-seven hyperlipidaemic individuals consumed three isoenergetic (mean 1770 kJ/d) supplements during three 1-month dietary phases: (1) full-dose almonds (50-100 g/d); (2) half-dose almonds with half-dose muffins; (3) full-dose muffins. Fasting blood samples were obtained at weeks 0 and 4 for the determination of FA concentrations. Almond intake (g/d) was found to be inversely associated with the estimated Framingham 10-year CHD risk score (P= 0·026). In both the half-dose and full-dose almond groups, the proportions of oleic acid (OA) and MUFA in the TAG fraction (half-almond: OA P= 0·003; MUFA P= 0·004; full-almond: OA P< 0·001; MUFA P< 0·001) and in the NEFA fraction (half-almond: OA P= 0·01; MUFA P= 0·04; full-almond: OA P= 0·12; MUFA P= 0·06) increased. The estimated Framingham 10-year CHD risk score was inversely associated with the percentage change of OA (P= 0·011) and MUFA (P= 0·016) content in the TAG fraction. The proportions of MUFA in the TAG and NEFA fractions were positively associated with changes in HDL-cholesterol concentrations. Similarly, the estimated Framingham 10-year CHD risk score was inversely associated with the percentage change of OA (P= 0·069) and MUFA content in the NEFA fraction (P= 0·009). In conclusion, the results of the present study indicate that almond consumption increases OA and MUFA content in serum TAG and NEFA fractions, which are inversely associated with CHD lipid risk factors and overall estimated 10-year CHD risk.

Indexed as

DietNutsPrunusAgedAged, 80 and overCholesterol, HDLCoronary DiseaseCross-Over StudiesDose-Response Relationship, DrugFatty AcidsFatty Acids, MonounsaturatedFatty Acids, NonesterifiedFemaleHumansHyperlipidemiasMaleCholesterol, HDLFatty AcidsFatty Acids, MonounsaturatedFatty Acids, NonesterifiedOleic AcidTriglycerides

Identifiers

PMID25138064
PMCPMC4189119
OpenAlexW2070635899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.